Efpeglenatide

Last updated
Efpeglenatide
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions. [1] [2] [3] [4] [5] [6] [7] Its developer is Hanmi Pharmaceutical. [8]

References

  1. ↑ Frias, Juan Pablo; Choi, JaeDuk; Rosenstock, Julio; Popescu, Luiza; Niemoeller, Elisabeth; Muehlen-Bartmer, Isabel; Baek, Seungjae (7 July 2022). "Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial". Diabetes Care. 45 (7): 1592–1600. doi:10.2337/dc21-2656. PMC   9274225 . PMID   35671039.
  2. ↑ Lam, Carolyn S.P.; Ramasundarahettige, Chinthanie; Branch, Kelley R.H.; Sattar, Naveed; Rosenstock, Julio; Pratley, Richard; Del Prato, Stefano; Lopes, Renato D.; Niemoeller, Elisabeth; Khurmi, Nardev S.; Baek, Seungjae; Gerstein, Hertzel C. (22 February 2022). "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial". Circulation. 145 (8): 565–574. doi: 10.1161/CIRCULATIONAHA.121.057934 . PMID   34775781. S2CID   244115633.
  3. ↑ Gerstein, Hertzel C.; Li, Zhuoru; Ramasundarahettige, Chinthanie; Baek, Seungjae; Branch, Kelley R.H.; Del Prato, Stefano; Lam, Carolyn S.P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed (28 March 2023). "Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial". Circulation. 147 (13): 1004–1013. doi: 10.1161/CIRCULATIONAHA.122.063716 . ISSN   0009-7322. PMID   36802715. S2CID   257066772.
  4. ↑ Pratley, Richard E.; Kang, Jahoon; Trautmann, Michael E.; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H.; Jacob, Stephan; Yoon, Kun-Ho (November 2019). "Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study". Diabetes, Obesity & Metabolism. 21 (11): 2429–2439. doi:10.1111/dom.13824. ISSN   1462-8902. PMC   6851541 . PMID   31264757.
  5. ↑ Pratley, Richard E.; Jacob, Stephan; Baek, Seungjae; Trautmann, Michael E.; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H.; Shaunik, Alka; Yoon, Kun-Ho (1 January 2022). "Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline". BMJ Open Diabetes Research & Care. 10 (1) e002207. doi:10.1136/bmjdrc-2021-002207. ISSN   2052-4897. PMC   8768911 . PMID   35042751.
  6. ↑ Gerstein, Hertzel C.; Li, Zhuoru; Ramasundarahettige, Chinthanie; Baek, Seungjae; Branch, Kelley R.H.; Del Prato, Stefano; Lam, Carolyn S.P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed (28 March 2023). "Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial". Circulation. 147 (13): 1004–1013. doi: 10.1161/CIRCULATIONAHA.122.063716 . PMID   36802715. S2CID   257066772.
  7. ↑ Gerstein, Hertzel C.; Sattar, Naveed; Rosenstock, Julio; Ramasundarahettige, Chinthanie; Pratley, Richard; Lopes, Renato D.; Lam, Carolyn S.P.; Khurmi, Nardev S.; Heenan, Laura; Del Prato, Stefano; Dyal, Leanne; Branch, Kelley (2 September 2021). "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes". New England Journal of Medicine. 385 (10): 896–907. doi: 10.1056/NEJMoa2108269 . ISSN   0028-4793. PMID   34215025. S2CID   235723092.
  8. ↑ Pharmaceutical, Hanmi. "Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"". www.prnewswire.com (Press release). Retrieved 5 November 2023.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.